Plasticell Limited

25 April 2023 — Stevenage, UK — Plasticell Ltd, a developer of stem cell technologies and advanced therapies, has announced today that it has entered into a strategic collaboration with Singapore-based LambdaGen. Together, the two companies will exploit genome editing technologies based on synthetic lambda integrases that allow specific insertion of large gene cassettes into…

Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) to specific blood cell lineages for use by GSK in its therapeutic research

Plasticell today announced it has partnered with Kings College London to progress preclinical trials of its artificial blood platelet product, manufactured from pluripotent stem cells.

Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.

7 February 2017, Stevenage UK: Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that the Companyís founder, Dr. Yen Choo, has been named ‘Best CEO in the Stem Cell Industry’ by European CEO magazine. This accolade in part recognises Plasticellís success in organic growth as well as its business model for…

Plasticell has announced the publication of peer-reviewed scientific research in the journal Stem Cells and Development, which demonstrates how the companyís award-winning platform technology can be used to discover novel cell culture protocols that expand specific populations of therapeutic stem cells present in cord blood.

Plasticell announces the completion of a two-part equity financing round, raising a total of £1.32 million from its shareholders and new investors.

Plasticell, the biotechnology company using combinatorial technologies for stem cell research and optimization of cell and gene therapy manufacturing, has announced it is collaborating with CellSpring, an innovative company that has developed a high throughput 3D cell culture system, the 3D Bloom Biopolymer Platform, which enables more informed “stop/go” decisions for preclinical candidates.

Plasticell, the biotechnology company using combinatorial technologies for stem cell research and the optimization of cell and gene therapy manufacturing, has announced the signing of a collaboration agreement with the National University of Ireland, Galway (NUI Galway) focused on methods of eradicating cancer stem cells.